Skip to content

Comparison of the effects of dexmedetomidine and ketamine on Oddi sphincter tone during ERCP

Comparison of the effects of dexmedetomidine and ketamine on Oddi sphincter tone during ERCP

Status
Recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT20230817059177N1
Enrollment
84
Registered
2023-10-21
Start date
2023-09-22
Completion date
Unknown
Last updated
2023-11-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

ERCP.

Interventions

Intervention 1: Intervention group one : The intervention group of Rotax ketamine (C13H16CINO) with a dose of 0.5 mg per kilogram of weight for 40 seconds intravenously one to three times by Hakim Meh

Sponsors

Ahvaz University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: ERCP candidate patients who need anesthesia, , in the age range of 18 to 65 years, not suffering from cardiovascular diseases, kidney or liver failure not addicted to drugs, convulsions, not having contraindications for the use of dexmedetomidine, ketamine, which are classified as class 1 and 2 of the association American Anesthesia (ASA) and II, I class are selected

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
The effectof dexmedetomidine on the tone of the sphincter of Audi based on the pain level. Timepoint: 5-10-20-30 min of study. Method of measurement: questionnaire.;The effect of ketamine drug on the sphincter of Audi, drug side effects. Timepoint: 5-10-20-30 min of study. Method of measurement: questionnaire.

Secondary

MeasureTime frame
Level of relaxation. Timepoint: 5-10-20-30 min of the study. Method of measurement: questionnaire.;Hypertention. Timepoint: 5-10-15-20 min of the study. Method of measurement: questionnaire.;Heartrate. Timepoint: in the procedure of study. Method of measurement: questionnaire.

Countries

Iran (Islamic Republic of)

Contacts

Public Contactmahshid vaziri

Ahvaz University of Medical Sciences

mahrokh.vardipour@gmail.com+98 61 3314 0000

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026